Abstract Body

Background

Despite 40 years of research, no vaccine has elicited broadly neutralizing antibodies (bNAbs) in outbred animals or humans. We showed that B cell precursor priming is the primary bottleneck to V2 apex bNAb induction (Habib et al., Sci Immunol 2026), and we hypothesized that this barrier can be overcome by enhancing B cell priming. Here, we used a novel germline-targeted HIV-1 Env expressed by simian-human immunodeficiency viruses (SHIVs) that increased precursor priming and elicited bNAbs in 93% of infected rhesus macaques (RMs).

Methods

We used a germline-targeted HIV-1 Env (OPT4) based on neutralization signature analysis (Bricault et al., Cell Host Microbe 2019) to create a novel SHIV.OPT4 that expressed a native-like tier 2 Env that was sensitive to neutralization by rhesus and human V2 apex bNAb precursors. The OPT4 Env has short segments of ZM233 and T250 substituted into the V1 and V2 loops, respectively, of CAP256SU, along with C-strand modifications to enhance V2 apex-precursor binding. We infected 16 RMs with SHIV.OPT4 or a variant (SHIV.OPT4-S) that contained a shielding glycan in the V2 loop and monitored for bNAb development.

Results

14 RMs showed typical infection kinetics, while two were rapid progressors and were euthanized. Of 14 evaluable animals, 13 developed V2 apex C-strand-directed heterologous neutralization, with breadth reaching up to 90% on a 21-virus panel within 12 to 36 weeks. Cryo-EM structural analysis of bNAbs isolated from 3 animals revealed canonical needle-like HCDR3 binding, typical of V2 apex bNAbs. To study the rapid bNAb development, we sorted epitope-specific B cells 12 weeks post-infection. The average number of V2 apex bNAb-like B cell lineages primed by SHIV.OPT4/OPT4-S was 11 per RM. This was in stark contrast to 15 other RMs infected with SHIV.Q23, SHIV.CAP256SU or SHIV.CH505, where the rate of priming was 0.27 lineages per RM (a 40-fold difference), or to 115 RMs infected with one of 16 different SHIVs followed for two years, where the rate of priming per week was ~0.03 (a 370-fold difference).

Conclusions

Our findings show that OPT4/OPT4-S Envs markedly increased V2 apex bNAb precursor priming, resulting in rapid induction of potent bNAbs in the serum of 93% of evaluable RMs. These results inform the design of mRNA-LNP and Env trimer protein vaccination trials currently underway in RMs and slated to begin in humans in early 2026 (HVTN 322).